-- Climb Bio (CLYM) has an average rating of buy and mean price target of $16.69, according to analysts polled by FactSet.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Ajanta Pharma (NSE:AJANTPHARM, BOM:532331) recorded a rise in its consolidated net profit to 2.67 billion Indian rupees in the fiscal fourth quarter ended March 31 from 2.25 billion rupees a year ago.Earnings per share climbed to 21.34 rupees from 18 rupees a year earlier, according to a Tuesday filing by the pharmaceutical company.Revenue from operations in fiscal Q4 also increased to 14.2 billion rupees from 11.7 billion rupees a year earlier, the filing said.